Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
July 19, 2020Iranian Journal of Psychiatry and Behavioral SciencesOpen Access

Metoclopramide-Induced Neuroleptic Malignant Syndrome: A Review Study

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Metoclopramide was previously assumed to be free of extrapyramidal side effects, but subsequent reports indicated it can cause extrapyramidal symptoms, drug-induced motor side effects, and neuroleptic malignant syndrome.

Population

20 patients from 20 articles reporting metoclopramide-induced neuroleptic malignant syndrome

Design

Systematic review

Key result

A 56-year-old man with schizophrenia developed a third, lethal episode of neuroleptic malignant syndrome despite a 45-month period without antipsychotic use, suggesting a trait vulnerability.

Authors

IGIdeh GhafourFEForouzan Elyasi

Discussion

Loading...

Member takes

Overview

NMS may recur fatally years after metoclopramide exposure; case reports leave open long-term risk stratification and prevention.

Study Design

Type

Case Report (n=1)

Multicenter

No

Structured PICO

P
Population
A 56-year-old man with schizophrenia who developed three episodes of neuroleptic malignant syndrome, the last occurring without recent antipsychotic use.
E
Exposure
Metoclopramide (review); Risperidone, clozapine, olanzapine, electroconvulsive therapy (ECT), and promethazine (case report).
O
Outcome
Treatment success and mortality associated with Neuroleptic Malignant Syndrome.safety

Neuroleptic Malignant Syndrome is a rare but potentially fatal complication that can be induced by metoclopramide or atypical antipsychotics, and may recur in vulnerable individuals even without recent antipsychotic exposure.

Cite This Study

Ghafour et al. (2020) conducted a case report in Neuroleptic Malignant Syndrome (n=1). Promethazine and ECT was evaluated on Recurrence of Neuroleptic Malignant Syndrome. A 56-year-old man with schizophrenia developed a third, lethal episode of neuroleptic malignant syndrome despite a 45-month period without antipsychotic use, suggesting a trait vulnerability.

synapsesocial.com/papers/6a9cacece4895faeb35d3573https://doi.org/10.5812/ijpbs.100888
View Full Paper
Ask AI
Bookmark
Share